Skip to main content
SpringerLink
Log in

Daiichi Sankyo: Engagiert in der Forschung. Im Einsatz für den Patienten

Ein neues Mitglied stellt sich vor

  • Sektion C
  • Published:
Forum Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. ClinicalTrials.gov (NCT03248492)

  2. ClinicalTrials.gov (NCT03329690)

  3. ClinicalTrials.gov (NCT03384940)

  4. Network NCC (2018) NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 1.2018. http://www.nccn.org . Zugegriffen: 7. Feb. 2018

  5. Zarrinkar P et al (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 114(14):2984–2992

    Article  CAS  Google Scholar 

  6. QuANTUM-R Studie ClinicalTrials.gov (NCT02039726)

  7. QuANTUM-First Studie ClinicalTrials.gov (NCT02668653)

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Daiichi Sankyo: Engagiert in der Forschung. Im Einsatz für den Patienten. Forum 33, 209–210 (2018). https://doi.org/10.1007/s12312-018-0429-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12312-018-0429-9

Search

Navigation